A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma

We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 1996-01, Vol.14 (2), p.219-222
Hauptverfasser:	WOOLLEY, P. V, SCHULTZ, C. J, RODRIGUEZ, G. I, GAMS, R. A, ROWE, K. W, DADEY, M. L, VON HOFF, D. D, MCPHILLIPS, J. J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Bronchogenic - drug therapy Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Drug Administration Schedule Female Humans Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Phospholipid Ethers - adverse effects Phospholipid Ethers - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and a dose of 300 mg/m2/day. Toxicities were gastrointestinal (nausea, vomiting, diarrhea), fatigue and liver function abnormalities. These were severe and resulted in the removal of some patients from study. No consistent pattern of bone marrow suppression was seen. No tumor regressions occurred in 14 evaluable patients including 5 with no prior therapy. We conclude that ilmofosine is inactive in this tumor at this dose and schedule.
ISSN:	0167-6997 1573-0646
DOI:	10.1007/BF00210794